Methotrexate Monotherapy for Unilateral Active Thyroid-Related
Eye Disease
Ayman G. Elnahry1 M.D., Ph.D., Joseph H.
Talbet2 B.A., Gehad A. Elnahry1M.D., Ph.D.
1Department of Ophthalmology,
Faculty of Medicine, Cairo
University, Cairo, Egypt.
2 College of Medicine, Howard University, Washington,
DC, USA.
Corresponding author, and correspondence to: Ayman G. Elnahry
M.D., Ph.D., Department of Ophthalmology, Cairo University, Faculty of
Medicine, Kasr Alainy street, Cairo, Egypt 11956. Phone: +20-1224927604.
Fax: +20223682030. E-mail:
ayman_elnahri@hotmail.com
Running title: Methotrexate for Active Thyroid Eye Disease
Ethical approval: This report was approved by Cairo University
research ethics committee and followed the tenets of the Declaration of
Helsinki
Financial support: None
Conflicts of Interest and Source of Funding: None
Keywords: Euthyroidism; Methotrexate; Monotherapy;
Thyroid-related eye disease.
Key Clinical Message: Active thyroid-related eye disease may be
safely and effectively managed using low-dose methotrexate monotherapy
especially in patients intolerant to steroid therapy.